April 4, 2017 / 11:40 AM / 8 months ago

BRIEF-Pieris pharma presents IND-enabling data

April 4 (Reuters) - Pieris Pharmaceuticals Inc:

* Pieris Pharmaceuticals presents IND-enabling data for bispecific immuno-oncology drug candidate, PRS-343, in poster session at the 2017 meeting of the American Association For Cancer Research (AACR)

* Pieris Pharma-data presented shows PRS-343 elicited robust t cell activation when engaging her2 on cell lines derived from tumors resistant to trastuzumab therapy

* Pieris Pharmaceuticals -PRS-343 was well tolerated and led to no significant findings in ind-enabling preclinical safety and non-human primate toxicology studies

* Pieris Pharma-4-1bb-mediated t cell activation by PRS-343 resulted in expression of broad spectrum of inflammatory cytokines associated with anti-tumor immune responses Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below